Skinvisible, INC

Skinvisible Pharmaceuticals announces significant achievements through its licensee Quoin Pharmaceuticals' progress in Netherton Syndrome treatment, potentially leading to the first FDA approval for a formulation using Skinvisible's Invisicare delivery technology.

Skinvisible's proprietary Invisicare technology demonstrates significant transdermal delivery of glucose-controlling agents, potentially revolutionizing obesity treatment.

Skinvisible Inc. has issued 350,000 units to accredited investors in a private placement, each unit consisting of one share of common stock and a warrant.

Skinvisible has filed a provisional patent application for a transdermal drug delivery system using its Invisicare technology for obesity treatments.

Skinvisible Inc. reported a net loss of $267,184 for the first quarter of 2026, with revenues remaining flat at $5,000, while operating expenses decreased slightly.

Skinvisible, Inc. reported continued net losses and a significant working capital deficit in Q3 2025, despite advancements in its Invisicare drug delivery technology and strategic partnerships.

Skinvisible, Inc. reported continued net losses and a worsening working capital deficit, raising substantial doubt about its ability to continue as a going concern, despite progress in its Invisicare drug delivery technology licensing efforts.

Skinvisible, Inc. reports consistent revenue of $5,000 for Q1 2025, maintaining its focus on licensing agreements and exploring transdermal delivery applications.

Skinvisible Inc. reports a net loss of $880,425 for the nine months ended September 30, 2024, while facing substantial doubt about its ability to continue as a going concern.

Skinvisible Inc. reports a net loss of $593,821 for the six months ended June 30, 2024, while facing substantial doubt about its ability to continue as a going concern.

Skinvisible Inc. reported a significant increase in net loss for fiscal year 2025, raising substantial doubt about its going concern status, despite ongoing positive clinical trial developments for its Invisicare technology.

Skinvisible, Inc. files its 10-K for the year ended December 31, 2024, highlighting ongoing efforts to license its Invisicare technology and advancements in clinical trials by its licensee, Quoin Pharmaceuticals.

Skinvisible, Inc. reports a net loss of $2.38 million for 2023, while highlighting advancements in clinical trials by its licensee, Quoin Pharmaceuticals.